HLH study looking at immune system and genes
Part of Blood & lymphatic, Bones, joints & muscles, Hormones & metabolism, Immune system & allergy, Skin clinical trials.
This study is for people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. Researchers want to collect medical data and blood samples to better understand HLH and find better ways to diagnose and treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of secondary HLH based on standard medical criteria.
- You must agree to have your data and blood samples stored and shared for future research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of two medicines, dexamethasone (a steroid) and intravenous immunoglobulin (antibodies from donated blood), can help treat a rare condition called hemophagocytic lymphohistiocytosis (HLH) that is triggered by an infection. It may help control the body's overactive immune response and improve organ function.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This study is a disease registry that collects medical information from children who have hemophagocytic lymphohistiocytosis (HLH) or are suspected to have it. It helps doctors better understand HLH and how it affects patients over time.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This trial tests an investigational drug, ELA026, for people with secondary hemophagocytic lymphohistiocytosis (sHLH), a rare condition where the immune system becomes overactive and damages organs. The study aims to see if ELA026 can calm the immune system and improve symptoms.
Hear when a new Lymphohistiocytosis, Hemophagocytic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.